A detailed history of Cullen/Frost Bankers, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 13 shares of BMRN stock, worth $866. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13
Previous 13 -0.0%
Holding current value
$866
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$74.43 - $92.22 $967 - $1,198
13 New
13 $1,000
Q3 2022

Nov 07, 2022

BUY
$82.16 - $96.94 $328 - $387
4 New
4 $0
Q4 2020

Feb 08, 2021

SELL
$72.61 - $90.2 $1,306 - $1,623
-18 Closed
0 $0
Q3 2020

Nov 05, 2020

BUY
$71.87 - $131.03 $1,293 - $2,358
18 New
18 $1,000
Q2 2020

Aug 05, 2020

SELL
$79.55 - $124.22 $9,148 - $14,285
-115 Closed
0 $0
Q1 2020

May 01, 2020

SELL
$71.37 - $96.85 $1,427 - $1,937
-20 Reduced 14.81%
115 $10,000
Q4 2019

Feb 06, 2020

SELL
$64.27 - $86.37 $8,098 - $10,882
-126 Reduced 48.28%
135 $11,000
Q3 2019

Nov 01, 2019

BUY
$67.4 - $85.11 $16,850 - $21,277
250 Added 2272.73%
261 $18,000
Q2 2019

Aug 01, 2019

SELL
$80.35 - $93.9 $3,294 - $3,849
-41 Reduced 78.85%
11 $1,000
Q1 2019

Apr 30, 2019

BUY
$84.2 - $98.62 $4,378 - $5,128
52 New
52 $5,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Cullen/Frost Bankers, Inc. Portfolio

Follow Cullen/Frost Bankers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.